NKTR
NKTR (NK-tumour recognition protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.
Overview
PPIase that catalyses the cis-trans isomerisation of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding. Component of a putative tumour-recognition complex involved in the function of NK cells.
IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Acute Myeloid Leukaemia.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NKTR (NK-tumour recognition protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.
- 1 · What it is
NKTR (NK-tumour recognition protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.
- 2 · What goes wrong in cancer
PPIase that catalyses the cis-trans isomerisation of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding. Component of a putative tumour-recognition complex involved in the function of NK cells.
- 3 · How drugs use it
No product in this corpus aims at NKTR yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:7833 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P30414 (protein name, function text, keywords and locations (REST API)); IntOGen NKTR (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
PPIase that catalyses the cis-trans isomerisation of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding. Component of a putative tumour-recognition complex involved in the function of NK cells. Location: Cell membrane (UniProt). Locus 3p22.1 (HGNC).
- Acute myeloid leukaemia: IntOGen driver in 1 cohort (AML)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"NKTR" OR ABSTRACT:"NKTR" OR TITLE:"natural killer cell triggering receptor" OR ABSTRACT:"natural killer cell triggering receptor" OR TITLE:"NK-tumor recognition protein" OR ABSTRACT:"NK-tumor recognition protein" OR TITLE:"p104" OR ABSTRACT:"p104" OR TITLE:"CypNK" OR ABSTRACT:"CypNK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NKTR, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentBempegaldesleukin
Shares A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma, A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC).